Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner

BJU International

Volumn 103, Issue 12, 2009, Pages 1729-1737

  Flaig, Thomas W ^b,c   Su, Lih Jen ^b   McCoach, Caroline ^b   Li, Yuan ^b   Raben, David ^a   Varella Garcia, Marileila ^b   Bemis, Lynne T ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Bladder cancer; Chemotherapy; Epithelial growth factor receptor; Vandetanib; Vascular endothelial growth factor receptor

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GEMCITABINE; PROTEIN P21; PROTEIN P27; VANDETANIB; VASCULOTROPIN RECEPTOR;

ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE SEQUENCE; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 67149143257     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08367.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66 (Pubitemid 46148091)
2. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005 23 : 4602 8
3. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003 22 : 3361 70
4. Wagner U, Sauter G, Moch H et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995 26 : 970 8
5. Rajjayabun PH, Keegan PE, Lunec J, Mellon JK. erbB receptor expression patterns in human bladder cancer. Urology 2005 66 : 196 200 (Pubitemid 41002227)
6. Xia G, Kumar SR, Hawes D et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006 175 : 1245 52
7. Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 2003 97 (Suppl. 2064 75
8. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002 62 : 4645 55
9. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005 92 (Suppl. 1 S6 13
10. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 2006 5 : 1883 94
11. Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005 16 : 1391 7
12. Tamura T, Minami H, Yamada Y et al. A phase I dose-escalation of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006 1 : 1002 9
13. Natale RB, Bodkin D, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC. Final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006 24 (Suppl.): Abstract No. 7000
14. Heymach JV, Johnson BE, Prager D et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC. Follow-up results. J Clin Oncol 2006 24 (Suppl.): Abstract No. 7016
15. Heymach J, Paz-Ares L, De Braud F et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006 24 (Suppl.): Abstract No. 7544
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984 22 : 27 55
17. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005 97 : 643 55
18. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 42
19. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 353 : 1673 84
20. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344 : 783 92
21. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003 21 : 2237 46
22. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004 22 : 785 94
23. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004 22 : 777 84
24. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006 176 : 787 92
25. McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. Combined treatment of bladder cancer cell lines with lapatanib and varying chemotherapy regimens - Evidence of schedule dependent synergy. Urology 2007 69 : 390 4
26. Zhou H, Kato A, Yasuda H et al. The induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure. Toxicol Appl Pharmacol 2004 200 : 111 20
27. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995 55 : 5187 90
28. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 101 : 13306 11
29. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 : 2129 39
30. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 : 1497 500